CN112218894A - 抗趋化因子样受体1抗体及其治疗应用 - Google Patents

抗趋化因子样受体1抗体及其治疗应用 Download PDF

Info

Publication number
CN112218894A
CN112218894A CN201980037001.4A CN201980037001A CN112218894A CN 112218894 A CN112218894 A CN 112218894A CN 201980037001 A CN201980037001 A CN 201980037001A CN 112218894 A CN112218894 A CN 112218894A
Authority
CN
China
Prior art keywords
seq
cmklr1
compound
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037001.4A
Other languages
English (en)
Chinese (zh)
Inventor
N·波里尔
C·马里
B·瓦努夫
V·高铁尔
C·特里洛
M·杜布尔多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSE Immunotherapeutics SA
Original Assignee
OSE Immunotherapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSE Immunotherapeutics SA filed Critical OSE Immunotherapeutics SA
Priority to CN202510632905.9A priority Critical patent/CN120484119A/zh
Publication of CN112218894A publication Critical patent/CN112218894A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201980037001.4A 2018-04-03 2019-04-03 抗趋化因子样受体1抗体及其治疗应用 Pending CN112218894A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510632905.9A CN120484119A (zh) 2018-04-03 2019-04-03 抗趋化因子样受体1抗体及其治疗应用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305395 2018-04-03
EP18305395.8 2018-04-03
PCT/EP2019/058358 WO2019193029A1 (en) 2018-04-03 2019-04-03 Anti-chemokin like receptor 1 antibodies and their therapeutic applications

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510632905.9A Division CN120484119A (zh) 2018-04-03 2019-04-03 抗趋化因子样受体1抗体及其治疗应用

Publications (1)

Publication Number Publication Date
CN112218894A true CN112218894A (zh) 2021-01-12

Family

ID=62046804

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980037001.4A Pending CN112218894A (zh) 2018-04-03 2019-04-03 抗趋化因子样受体1抗体及其治疗应用
CN202510632905.9A Pending CN120484119A (zh) 2018-04-03 2019-04-03 抗趋化因子样受体1抗体及其治疗应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510632905.9A Pending CN120484119A (zh) 2018-04-03 2019-04-03 抗趋化因子样受体1抗体及其治疗应用

Country Status (11)

Country Link
US (2) US20210147558A1 (enExample)
EP (2) EP4656247A2 (enExample)
JP (2) JP2021520210A (enExample)
KR (2) KR102802041B1 (enExample)
CN (2) CN112218894A (enExample)
AU (1) AU2019247068A1 (enExample)
BR (1) BR112020020118A2 (enExample)
CA (1) CA3102607A1 (enExample)
IL (2) IL277701A (enExample)
MA (1) MA52174A (enExample)
WO (1) WO2019193029A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114786722A (zh) * 2019-10-09 2022-07-22 Ose免疫疗法公司 抗类趋化因子受体1人源化抗体及其治疗应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730705B2 (en) * 2019-05-02 2023-08-22 The Board Of Trustees Of The Leland Stanford Junior University Small molecule CMKLR1 antagonists in inflammatory disease
EP3804754A1 (en) * 2019-10-09 2021-04-14 OSE Immunotherapeutics Cmklr1 agonists having a resolvin e1-like capability and their therapeutic applications
EP4279142A4 (en) 2021-01-15 2024-12-04 Reel Tech Co., Ltd. PORTABLE EMERGENCY ESCAPE DEVICE
US11986512B2 (en) 2021-10-26 2024-05-21 Thetis Phamaceuticals LLC Compositions and methods for cancer therapy
WO2024028508A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Anti-chemokin like receptor 1 antibody or antigen-binding fragment thereof for use in the treatment of conditions associated with netosis
WO2024028509A2 (en) 2022-08-05 2024-02-08 Ose Immunotherapeutics Treatment of an inflammation-associated disease in a patient expressing high chemerin level

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086966A1 (en) * 2001-07-09 2004-05-06 Valerie Wittamer Compositions and methods comprising a ligand of ChemerinR
US20090280113A1 (en) * 2008-05-10 2009-11-12 Kareem Graham Target for regulating multiple sclerosis
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
WO2013109543A1 (en) * 2012-01-20 2013-07-25 The Board Of Trustees Of The Leland Stanford Junior University Small molecule cmklr1 antagonists in demyelinating disease
US9195150B2 (en) * 2012-02-06 2015-11-24 Asml Netherlands B.V. Lithographic apparatus comprising a support for holding an object, and a support for use therein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040086966A1 (en) * 2001-07-09 2004-05-06 Valerie Wittamer Compositions and methods comprising a ligand of ChemerinR
US20090280113A1 (en) * 2008-05-10 2009-11-12 Kareem Graham Target for regulating multiple sclerosis
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J DINESH KUMAR等: "The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells", 《BRITISH JOURNAL OF CANCER》, vol. 114, pages 1152 - 1159, XP002782560, DOI: 10.1038/bjc.2016.93 *
李海等: "人趋化因子受体CCR5胞外片段的融合表达与纯化", 《免疫学杂志》, vol. 25, no. 1, pages 39 - 47 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114786722A (zh) * 2019-10-09 2022-07-22 Ose免疫疗法公司 抗类趋化因子受体1人源化抗体及其治疗应用

Also Published As

Publication number Publication date
US20210147558A1 (en) 2021-05-20
JP2024105648A (ja) 2024-08-06
IL277701A (en) 2020-11-30
CN120484119A (zh) 2025-08-15
WO2019193029A1 (en) 2019-10-10
AU2019247068A1 (en) 2020-10-22
IL321209A (en) 2025-07-01
MA52174A (fr) 2021-02-17
KR102802041B1 (ko) 2025-04-30
KR20210006359A (ko) 2021-01-18
BR112020020118A2 (pt) 2021-02-23
KR20250065423A (ko) 2025-05-12
US20240400698A1 (en) 2024-12-05
EP3774899A1 (en) 2021-02-17
EP4656247A2 (en) 2025-12-03
JP2021520210A (ja) 2021-08-19
CA3102607A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
KR102802041B1 (ko) 항-케모카인 유사 수용체 1 항체 및 이의 치료적 용도
JP6877500B2 (ja) ＴＧＦ−βに特異的な抗体
AU2018201333B2 (en) DKK1 Antibodies And Methods Of Use
KR101643005B1 (ko) 항ｎｒ１０ 항체 및 그의 이용
KR101931591B1 (ko) 항－ｉｌ－２３ 항체
KR102452349B1 (ko) Ceacam1에 대한 인간화 항체
KR20100061834A (ko) 개량된 항체분자
KR20160044043A (ko) Gitr 항원 결합 단백질
KR20140091736A (ko) 항슈도모나스 ｐｓｌ 및 ｐｃｒｖ 결합 분자를 이용한 병용 요법
KR102815628B1 (ko) 인간화 항-il17a 항체 및 이의 용도
KR20210104064A (ko) 항-il-27 항체 및 그의 용도
KR20250160366A (ko) 항-il-27 항체 및 이의 용도
KR20210068065A (ko) 안타고니스트
KR20160062207A (ko) 항ｎｒ１０ 항체 및 그의 이용
CN114786722A (zh) 抗类趋化因子受体1人源化抗体及其治疗应用
TW202313110A (zh) 癌症之治療
CN112175087B (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
KR20240019295A (ko) 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
CN116496405A (zh) 一种靶向pd-l1和cd47的双功能融合蛋白及其用途
CN117460529A (zh) 抗icos抗体的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210112

RJ01 Rejection of invention patent application after publication